Status: Recruiting
A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation
This study is to evaluate the safety, tolerability, PK, and preliminary efficacy of NTS071 in adults with TP53 Y220C-mutated solid tumors.
Participants needed: 220
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Nutshell Therapeutics (Shanghai) Co., LTD.Updated: Jun 24, 2026Locations: 2
Eligibility criteria
Male or female subjects, ≥ 18 years [+5]
Known CNS primary tumor and active or untreated CNS metastases [+5]